On November 5, 2026 NORROY BIOSCIENCE (NORROY), a late-stage clinical biotechnology company focused on innovative targeted radiopharmaceuticals, reported that its proprietary pipelines were featured in eight Top Rated Oral Presentations (TROP) and three e-posters at the 39th Annual Congress of the European Association of Nuclear Medicine (EANM’26), held from October 17 to 21 in Vienna, Austria, with the corresponding data presented during the congress.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The presentations further highlighted NORROY’s early- and late-stage radiopharmaceutical pipelines, including the first China-originated innovative radiopharmaceutical having received both Breakthrough Therapy Designation (BTD) and Fast Track Designation (FTD), as well as the first China-originated terbium-161-based radiopharmaceutical for prostate cancer. The presentations and e-Posters featured well-established radionuclides used in diagnostic imaging and targeted radioligand therapy, including 18F, 68Ga, and 177Lu, as well as the next-generation therapeutic radionuclide, 161Tb. It also explored targets including ACP3 and GPC3, with indications spanning from prostate cancer, renal cell carcinoma to hepatocellular carcinoma, neuroendocrine tumors, small cell lung cancer and primary aldosteronism.
During the congress, NORROY hosted its themed ecosystem forum, the KUNLUN SALON, which was chaired by Thomas Tulip, Ph.D., Chief Business Officer (CBO) of NORROY, and reached preliminary cooperation intentions with Esente Healthcare and other international partners. The collaborations will focus mainly on the development of radiopharmaceutical automation equipment, further expanding NORROY’s network of global industry partners.
Oliver Sartor, M.D., Chairman of NORROY’s Scientific Advisory Board and an internationally recognized prostate cancer expert, delivered in the congress an oral presentation titled "Initial Safety and Efficacy of 177Lu-NYM032 in Progressive mCRPC: A Phase I–II Study" and also participated in the KUNLUN SALON.
NORROY presented multiple molecular imaging studies targeting carbonic anhydrase IX (CAIX) in clear cell renal cell carcinoma (ccRCC). Research results involving 68Ga-NYM096 were explored with respect to lesion detection in ccRCC, one-stop-shop imaging for von Hippel–Lindau (VHL) syndrome, and the characterization of cystic renal masses. Separately, another radiotracer, 18F-NYM124, was evaluated in a prospective head-to-head comparison with 18F-FDG PET/CT, further investigating the potential application of CAIX-targeted molecular imaging in renal cancer diagnosis.
In prostate cancer, NORROY presented research on PSMA-targeted radiopharmaceutical candidates. 161Tb-labeled NYM032 was evaluated in a preliminary first-in-human, low-dose study in patients with metastatic castration-resistant prostate cancer (mCRPC). In addition, research on the ACP3-targeted candidate, 68Ga/177Lu-NY129, revealed its potential applications in molecular imaging for prostate cancer.
Other studies presented included preclinical evaluation of 68Ga/177Lu-NY123, a GPC3-targeted radiotheranostic candidate for hepatocellular carcinoma (HCC); 68Ga-NYM184, a CXCR4-targeted radiotracer for PET imaging; and 177Lu-NYM158, an SSTR2-targeted radiopharmaceutical candidate being investigated for treating aggressive neuroendocrine neoplasms and small cell lung cancer.
During EANM’26, NORROY showcased its integrated "Radiopharmaceuticals + Equipment" strategy at booth 267, highlighting developments in AI-enabled drug discovery, automated radiopharmaceutical manufacturing and unmanned production support systems.
The exhibition featured the Mortenon M1 multifunctional synthesis module, the Mortenon P1 automated production line, the Mortenon S3/S4 radionuclide dispensing modules, and the Mortenon D2 radiopharmaceutical transport containers, demonstrating NORROY’s equipment portfolio for radiopharmaceutical production and handling/transporting.
Through continued R&D and investment in radiopharmaceutical innovation, clinical development and automation technologies, NORROY aims to advance its pipelines and strengthen collaboration with global partners to support the development of nuclear medicine and radiotheranostics.
(Press release, Norroy Bioscience, NOV 5, 2026, View Source [SID1234674354])